Certara (NASDAQ:CERT) Stock Gets Price Target Bump from Barclays

Certara (NASDAQ:CERT) had its price objective raised by investment analysts at Barclays from $9.00 to $12.00 in a research report issued on Friday, Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Barclays‘s price objective indicates a potential downside of 0.07% from the company’s previous close.

Several other analysts have also issued reports on the stock. Weiss Ratings lowered shares of Certara from a “sell (d)” rating to a “sell (d-)” rating in a research report on Thursday, October 8th. UBS Group reaffirmed a “neutral” rating and set a $13.00 price objective on shares of Certara in a research note on Friday. KeyCorp lifted their price objective on Certara from $9.00 to $12.00 and gave the stock an “overweight” rating in a report on Friday, October 16th. Finally, TD Cowen boosted their target price on Certara from $9.00 to $11.00 and gave the company a “buy” rating in a research note on Tuesday, October 13th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $9.73.

Certara Trading Down 1.4%

Shares of CERT traded down $0.17 during mid-day trading on Friday, reaching $12.01. The company’s stock had a trading volume of 1,032,012 shares, compared to its average volume of 3,392,518. Certara has a 52 week low of $4.45 and a 52 week high of $12.31. The stock has a market cap of $1.83 billion, a PE ratio of -26.75 and a beta of 1.30. The company’s fifty day moving average price is $9.26 and its two-hundred day moving average price is $7.33. The company has a current ratio of 2.55, a quick ratio of 2.55 and a debt-to-equity ratio of 0.30.

Certara (NASDAQ:CERT) last released its earnings results on Thursday, November 5th. The company reported $0.09 EPS for the quarter, meeting the consensus estimate of $0.09. The company had revenue of $94.90 million for the quarter, compared to analyst estimates of $92.01 million. Certara had a negative net margin of 16.75% and a positive return on equity of 3.86%. The firm’s quarterly revenue was down 9.3% compared to the same quarter last year. During the same quarter last year, the firm earned $0.14 EPS. Certara has set its FY 2026 guidance at 0.310-0.340 EPS. On average, analysts predict that Certara will post 0.21 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. purchased a new position in shares of Certara in the second quarter worth $123,259,000. Dimensional Fund Advisors LP raised its holdings in Certara by 2.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 8,562,508 shares of the company’s stock valued at $48,806,000 after buying an additional 175,024 shares during the last quarter. Haveli Investment Management LLC purchased a new stake in Certara during the 2nd quarter valued at $48,470,000. Jefferies Financial Group Inc. purchased a new stake in Certara during the 2nd quarter valued at $46,446,000. Finally, Kopion Asset Management LLC boosted its position in Certara by 44.2% during the 2nd quarter. Kopion Asset Management LLC now owns 1,858,539 shares of the company’s stock valued at $12,173,000 after buying an additional 570,087 shares during the period. Institutional investors own 73.96% of the company’s stock.

Certara News Summary

Here are the key news stories impacting Certara this week:

• Positive Sentiment: Certara forecast 2026 revenue of $427.2 million to $431.4 million, well above the $380.9 million analyst consensus. Its EPS outlook of $0.31 to $0.34 also reaches or exceeds the $0.31 consensus midpoint, signaling improved expectations. Why Did Certara Shares Climb After Its Latest Update?
• Positive Sentiment: Third-quarter revenue of $94.9 million topped analysts’ $92.01 million estimate, and earnings of $0.09 per share met or exceeded consensus estimates cited in reports. Coverage highlighted software revenue growth reaching double digits for the first time in two years, alongside expanding margins. Certara Reports Third Quarter 2026 Financial Results Q3 Earnings Call Highlights
• Neutral Sentiment: Certara appointed Grant Peterson as chief product officer. The reports did not indicate an immediate financial impact from the leadership change. Certara Reports Third Quarter 2026 Financial Results
• Negative Sentiment: Despite beating revenue expectations, quarterly revenue fell 9.3% year over year, and EPS declined from $0.14 to $0.09. Those comparisons may temper optimism about the results. Certara Tops Q3 Earnings and Revenue Estimates

Certara Company Profile

Certara is a global provider of software and services that support drug development and regulatory approval. The company helps biopharmaceutical and pharmaceutical organizations use quantitative methods, modeling and simulation, and regulatory science to improve decisions throughout the development process.

Its software portfolio includes platforms for pharmacometric modeling and simulation, clinical trial design and analysis, pharmacology and safety assessment, data visualization, and regulatory submission management.